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Abstract
Objectives To assess how often stratified randomisation is used, whether
analysis adjusted for all balancing variables, and whether the method
of randomisation was adequately reported, and to reanalyse a previously
reported trial to assess the impact of ignoring balancing factors in the
analysis.
DesignReview of published trials and reanalysis of a previously reported
trial.
Setting Four leading general medical journals (BMJ, Journal of the
American Medical Association, Lancet, and New England Journal of
Medicine) and the second Multicenter Intrapleural Sepsis Trial (MIST2).
Participants 258 trials published in 2010 in the four journals. Cluster
randomised, crossover, non-randomised, single arm, and phase I or II
trials were excluded, as were trials reporting secondary analyses, interim
analyses, or results that had been previously published in 2010.
Main outcome measuresWhether the method of randomisation was
adequately reported, how often balanced randomisation was used, and
whether balancing factors were adjusted for in the analysis.
Results Reanalysis of MIST2 showed that an unadjusted analysis led
to larger P values and a loss of power. The review of published trials
showed that balanced randomisation was common, with 163 trials (63%)
using at least one balancing variable. The most common methods of
balancing were stratified permuted blocks (n=85) and minimisation
(n=27). The method of randomisation was unclear in 37% of trials. Most
trials that balanced on centre or prognostic factors were not adequately
analysed; only 26% of trials adjusted for all balancing factors in their
primary analysis. Trials that did not adjust for balancing factors in their
analysis were less likely to show a statistically significant result
(unadjusted 57% v adjusted 78%, P=0.02).
Conclusion Balancing on centre or prognostic factors is common in
trials but often poorly described, and the implications of balancing are
poorly understood. Trialists should adjust their primary analysis for
balancing factors to obtain correct P values and confidence intervals
and to avoid an unnecessary loss in power.
Introduction
The randomised controlled trial is considered the ideal study
design for assessing the effect of an intervention, as it is the
only method of ensuring that no systematic differences exist
between treatment groups. However, differences between
treatment arms in important prognostic factors can still arise by
chance. Such differences may cause some to question the
validity of the trial results. Many trials use balanced
randomisation to ensure a similar distribution between treatment
groups in important variables thought to influence outcome,
such as age and disease stage. Balanced randomisation involves
selecting certain baseline covariates (called balancing variables)
and incorporating them into the randomisation scheme in a way
that forces a certain degree of balance between treatment arms.
Common methods of balancing are minimisation1 or permuted
blocks within strata.2
There is overwhelming evidence from the statistical literature
to show that variables used in the randomisation process should
subsequently be adjusted for in the analysis,3-8 as failure to do
so can result in P values that are too large and confidence
intervals that are too wide; this leads to a decrease in power and
a reduction in type I error rate, which could potentially lead to
an incorrect conclusion that the treatment has no benefit. This
is because balanced randomisation introduces correlation
between treatment groups, which violates the statistical
assumption that all patients are independent.4 This correlation
between treatment groups occurs because balanced
randomisation forces the outcomes between treatment arms to
be similar (apart from any treatment effect). This is seen in
figure 1⇓, where simulated data shows that outcomes between
the two treatment groups are correlated under balanced
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randomisation. A more detailed discussion of these issues can
be found elsewhere.4
It is therefore important to adjust for all balancing factors in the
analysis to ensure correct P values and confidence intervals.
Giving a clear description of both the method of randomisation
and the method of analysis is also important to allow readers to
properly judge trial results.9 For example, if the method of
randomisation is unclear, readers will be unable to judge whether
the method of analysis was adequate. We assessed the potential
impact of unadjusted analyses after balanced randomisation had
been used; determined how often trials balance on prognostic
factors or recruiting centre, and whether these factors were
appropriately adjusted for in the analysis. We also determined
whether the method of randomisation was adequately reported.
Methods
Reanalysis of the MIST2 trial
To assess the impact of an unadjusted analysis after balanced
randomisation has been used, we reanalysed data from a
published randomised trial. The secondMulticenter Intrapleural
Sepsis Trial (MIST2)10 found that a combination of tissue
plasminogen activator and DNase was effective in reducing the
size of pleural effusions in patients with pleural infection.
Patients were randomised using minimisation, balancing on the
size of the pleural effusion at baseline, whether the infection
was acquired in hospital or not, and the presence of purulent
pleural fluid.
We reanalysed the primary outcome (size of pleural effusion)
and the two major secondary outcomes (need for surgery and
time to hospital discharge). We used both adjusted and
unadjusted analyses and compared the results.
Review of trials published in leading medical
journals
One author (BCK) searched the electronic table of contents of
the BMJ, Journal of the AmericanMedical Association, Lancet,
and New England Journal of Medicine between January and
December 2010 for reports of parallel group, individually
randomised trials.We discarded articles with titles that indicated
non-randomised trials. All other articles were downloaded and
assessed for eligibility. Cluster randomised, crossover, single
arm, and phase I or II trials were excluded, as were
non-randomised studies. We excluded cluster randomised trials
because of possible differences compared to individually
randomised trials in types of balancing variables used, and we
excluded phase I and II trials as we wanted to focus on large
scale phase III trials that had the ability to change clinical
practice. To avoid double counting we additionally excluded
articles reporting secondary analyses, interim analyses, or results
that had been previously published in 2010. A second author
(TPM) repeated this process for articles published between
March and May 2010 to assess agreement in the articles
identified and those classified as eligible. Agreement between
authors was 100% for both.
We extracted data onto a standardised form, which was piloted
on several articles from 2009. One author (BCK) extracted data
from all trials and the other author (TPM) extracted data from
20 randomly selected trials to assess agreement between authors.
Discrepancies were resolved by discussion. Agreement was
assessed for whether the allocation ratio was specified, the
method of randomisation, whether centre was used as a
balancing factor and adjusted for in the analysis, and whether
any prognostic variables were used as balancing factors and
adjusted for in the analysis. Overall agreement between the two
authors was 96%.
We chose to review articles from the four selected medical
journals to enable comparisons with previously reported reviews
of the same journals.11 12 We reviewed articles published during
one calendar year because a previous report12 found over 200
eligible trials during the same time frame from the same group
of journals, which would allow good estimates of how often
balanced randomisation is used and how often the balancing
factors are accounted for in the analysis.
Trials were classified as adjusting for balancing factors if the
article stated that balancing factors had been adjusted for or if
they included the balancing factors in a list of adjustment factors.
The trials were classified as not adjusting if they stated an
unadjusted analysis was done or if they listed those factors that
had been adjusted for but did not list the balancing factors. For
trials that provided summary outcome information (means and
standard deviations or proportions in each group) we calculated
the crude (unadjusted) treatment effect. If this result matched
the treatment effect given in the text, we listed the trial as
unadjusted. Otherwise the trial was listed as unclear. We listed
as unclear any additional trials that were not classified as
adjusted or unadjusted.
If both adjusted and unadjusted results were presented but
neither was classified as the primary analysis, we tookwhichever
result was presented first as the primary analysis. When the
primary outcome was not stated, we took it to be the first
outcome listed.
Results
Reanalysis of MIST2
Supplementary table 1 shows the differences between adjusted
and unadjusted analyses. Unadjusted analyses led to larger P
values for need for surgery (a 1.8-fold increase; 0.095 v 0.175
for adjusted and unadjusted, respectively) and time to hospital
discharge (a fourfold increase; 0.011 v 0.044). For the size of
the pleural effusion both analysis methods gave identical P
values (P=0.005); however, this was because the unadjusted
analysis had a larger treatment effect, owing to a baseline
imbalance in the size of the pleural effusion between treatment
groups. The width of the confidence interval for the unadjusted
analysis, however, was 56% wider than that of the adjusted
analysis, which could lead to a reduction in power of over 20%.4
The unadjusted analysis for need for surgery led to a smaller
confidence interval than the adjusted analysis. This phenomenon
has been explained previously13; for binary and time to event
outcomes, adjusting for prognostic factors increases both the
standard error and the estimated treatment effect (given there
is a treatment effect). This leads to wider confidence intervals
but smaller P values, meaning that adjusted analyses will still
increase power for binary and time to event outcomes. Previous
studies have shown that if balancing or prognostic factors are
well chosen, increases in power can be substantial (for example,
>10%).4 13 14Although the confidence interval for the unadjusted
analysis is smaller than that of the adjusted analysis, it is still
incorrect in the sense that the type I error rate will be smaller
than it should be; by comparison the type I error rate for the
adjusted analysis will be correct.
Review of trials published in leading medical
journals
Overall, 304 trials were identified, of which 46 were excluded:
17 were cluster randomised trials, 11 phase I or II trials, nine
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previously reported trials from the same year, four were
crossover trials, three carried out secondary analyses, one did
an interim analysis, and one was a non-randomised trial. In total
258 trials were included (fig 2⇓). Table 1⇓ shows the
characteristics of the included trials.
Randomisation
In 96 trials (37%) the method of randomisation was unclear.
Among those trials that reported the method of randomisation,
four (2%) used simple randomisation, 125 (77%) used permuted
blocks (85 with stratification and 40 without), 29 (18%) used
minimisation, and four (2%) used another method.
Among trials using permuted blocks, 42 (34%) did not state the
block size. Fifteen trials (12%) used random block sizes,
whereas in 42 trials (34%) this was not clear. The median block
size used (taking the largest when random block sizes were
used) was 8 (interquartile range 4-10, 10-90th centile 4-20).
Sixty nine trials (83%) used a block size less than 12.
Twenty seven of 29 trials (93%) that used minimisation did not
specify whether it was deterministic—that is, completely
non-random. The two trials that reported using an element of
probability did not state the probability of receiving the favoured
treatment.
Use of balanced randomisation
Randomisation was balanced on centre in 120 trials (47%) and
on prognostic factors in 111 trials (43%). In total, 163 trials
(63%) balanced on at least one variable (centre or a prognostic
factor). Most trials balanced on only one or two prognostic
factors (n=87; 78%), whereas 24 trials (22%) used between
three and eight factors.
Analysis of trials using balanced randomisation
Of those trials that balanced on centre, only 31 (26%) reported
adjusting the primary analysis for centre; 4 (3%) adjusted for
centre in a secondary analysis, 68 (57%) did not adjust for
centre, and 17 (14%) were unclear (table 2⇓).
Similarly, only 40 trials (36%) that used prognostic factors in
their randomisation adjusted for all of these factors in the
primary analysis; 4 (4%) adjusted for some factors, 10 (9%)
adjusted for all factors in a secondary analysis, 45 (41%) did
not adjust for any factors, and 12 (11%) were unclear.
Overall, only 42 (26%) of trials that used at least one balancing
factor in their randomisation (either centre or a prognostic factor)
appropriately adjusted for all factors in the primary analysis; 8
(5%) adjusted for all factors in a secondary analysis, 3 (2%)
adjusted for centre but not for prognostic factors, 14 (9%)
adjusted for prognostic factors but not centre, 74 (45%) did not
adjust for any balancing factors, and 22 (14%) were unclear.
Three of 10 trials that adjusted for all prognostic factors in a
secondary analysis, two of four trials that adjusted for centre in
a secondary analysis, and three of eight trials that adjusted for
all balancing factors in a secondary analysis gave equal weight
to both the adjusted and unadjusted analyses, but presented the
unadjusted analysis first. The remaining trials gave more weight
to the unadjusted analysis—for example, by presenting only
unadjusted results in the abstract, text, or key figures or tables.
None of these trials had specified which of the two analysis
methods was the primary.
Difference in significance rates between adjusted
and unadjusted analyses
Trials that adjusted for all balancing factors were more likely
to find a statistically significant result (n=39/50, 78%) compared
with trials that did not adjust for any balancing factors (n=42/74,
57%; odds ratio (adjusted v unadjusted) 2.70, P=0.02), indicating
that trials could be losing power through not adjusting. These
results should be interpreted cautiously, however, as this
difference could in part be due to confounding. Fourteen of 22
(64%) trials that did not clarify whether the analysis was
adjusted found a statistically significant result, as did 12/17
(71%) trials that adjusted for some but not all balancing factors.
Discussion
Balanced randomisation introduces correlation between
treatment groups, violating the statistical assumption that all
observations are independent. Accounting for balancing factors
in the analysis is necessary to obtain correct P values and avoid
a loss in power. Most trials reviewed (63%) used balanced
randomisation; however only 26% appropriately adjusted for
all balancing factors in their primary analysis, indicating that
the majority of trials using balanced randomisation may be
reporting overly conservative results.
Reporting of randomisation
Many trial reports made no attempt to explain the method of
randomisation and simply reported that patients were
randomised to different treatments (see box for examples). Other
trials attempted to explain the method of randomisation but did
so poorly, stating only that randomisation was done using
computer generated random numbers or a random numbers
table. These explanations are not adequate as almost all methods
of randomisation can be done using random numbers. The
method of randomisation can have a large effect on the
possibility of selection bias in open label trials,12 15 16 and the
appropriate method of analysis also depends on the method of
randomisation. Therefore the method of randomisation should
be clearly explained so that readers are able to determine
whether appropriate methods were used. One policy that would
add clarity to reporting is for authors to explicitly state when
randomisation was not stratified (see seventh example in box)
and when an unadjusted analysis was done. Currently, most
trials only mention stratification when it was used but do not
explicitly state when it was not used. This makes it difficult to
judge whether stratification was truly not used or if it was used
but was not reported.
Analysis of trials after stratified randomisation
We have found that ignoring balancing factors in the analysis
after stratified randomisation can impact on trial results. In the
secondMulticenter Intrapleural Sepsis Trial (MIST2), ignoring
the balancing factors led to a 56% increase in the width of the
confidence interval for the primary outcome (which could lead
to a reduction in power of over 20%) and led to 1.8-fold and
4.0-fold increases in the P values for need for surgery and time
to discharge, respectively. These results are consistent with an
example given by a randomised trial comparing two
chemotherapy treatments for liver cancer.6 Randomisation was
balanced across 18 centres; ignoring centre in the analysis led
to a 4.5 fold increase in the P value (0.027 v 0.006 for unadjusted
and adjusted, respectively).
We found that 71% of trials that balanced on centre and 55%
that balanced on prognostic factors did not appropriately adjust
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Explanations of randomisation method
Poor explanations of randomisation method
Patients were then randomly assigned to [treatment] or placebo for 12 weeks
Patients were randomly assigned to receive usual care or [treatment], according to a sequence of computer-generated random numbers,
with stratification on the basis of the study site
Qualifying participants underwent randomisation and started the assigned study medication as inpatients
Within two weeks of recruitment we randomly allocated sealed sample packs . . . into two groups using random number tables
Patients were randomly assigned by a computer program to receive either [treatment] three times a day or [placebo] thrice daily
Good explanations of randomisation method
Eligible subjects were randomly assigned to receive one of the three study medications in a 1:1:1 ratio. Treatment assignments were
performed centrally according to a computer-generated random schedule in permuted blocks of three within age strata (<6 years and
≥6 years) and within study site
After providing written informed consent, [patients] were randomly assigned in a 1:1:1 ratio (with the use of sealed envelopes) to one
of three study groups in permuted blocks of six or nine with no stratification
Patients were randomly assigned (1:1) by simple randomisation to the [intervention] or to standard care (control group). A project
statistician generated the randomisation numbers with a random number generating program
for all factors in their analyses. Trials that adjusted for balancing
factors in the analysis were more likely to show a statistically
significant result, potentially because of the increased power
owing to adjustment.
Comparison with other studies
Two previous reviews in 1997 and 2002 analysed the same
journals we reviewed and found the method of randomisation
was unclear in 54% and 34% of trials, respectively.11 12 The
findings from one of the reviews are similar to our own (37%
of trials did not specify the method of randomisation), indicating
that while reporting of the randomisation method may have
improved between 1997 and 2002 there has been little
improvement subsequently, which we hope will change with
the adoption of the 2010 consolidated standards of reporting
trials (CONSORT) statement.9 12 We found the number of trials
balancing for centre and prognostic factors to be similar to that
reported previously.11
Limitations of the study
Our review was limited to articles published in four major
medical journals, which is unlikely to be a representative sample
as articles published in other medical journals are likely to have
different reporting standards. Journals adopting the CONSORT
statement have better reporting standards than others,17 so it is
likely that overall reporting standards are worse than those we
found. The majority of trials were identified and reviewed by
one author, with only a subset of trials identified or reviewed
by a second author. Although agreement between authors was
high (100% for trial identification, 96% for data extraction),
human error remains possible.
Conclusions and policy implications
Balanced randomisation induces correlation between treatment
groups, which can lead to P values that are too large and
confidence intervals that are too wide if balancing factors are
not accounted for in the analysis. This is unlikely to affect trials
that show overwhelming evidence in favour of a treatment
difference, but could affect interpretations in the presence of
moderate evidence. The difference between adjusted and
unadjusted analyses depends on whether the balancing factors
are associated with outcome. If balancing factors are not
prognostic, then ignoring them in the analysis will have little
impact; however, balancing factors are generally chosen because
they are thought to be prognostic and so should generally be
associated with outcome. Because the analysis method should
be prespecified before data analysis (as retrospective model
selection where authors use statistical significance tests to
determine which factors should be adjusted for can lead to type
I error rates that are too high7), we recommend the protocol or
statistical analysis plan should prespecify that all balancing
factors are adjusted for in the analysis.
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Tables
Table 1| Characteristics of included trials. Values are number (percentage) of trials unless stated otherwise
Trials (n=258)Characteristics
557 (232-1679)Median (interquartile range) No of patients
No of treatment arms:
213 (83)2
34 (13)3
11 (5)≥4
Primary outcome:
64 (25)Continuous
100 (39)Binary
81 (31)Time to event
11 (4)Rate
2 (1)Other
No of centres involved:
22 (9)Single
206 (80)Multiple
30 (12)Not stated
Allocation ratio:
110 (43)1:1
19 (7)Not 1:1
129 (50)Not stated*
*Most trials that did not state the allocation ratio had a similar number of patients in all treatment arms, indicating the ratio was likely to be 1:1
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Table 2| Reporting and analysis of trials
No (%) of trials (n=258)Variables
Method of randomisation:
4 (2)Simple randomisation
40 (16)Permuted blocks without stratification
85 (33)Permuted blocks with stratification
29 (11)Minimisation
4 (2)Other
96 (37)Unclear
120 (47)Balanced on centre
Adjustment for centre (n=120)*:
31 (26)Adjusted primary analysis
4 (3)Adjusted secondary analysis
68 (57)Not adjusted
17 (14)Unclear
111 (43)Balanced on prognostic factors
Adjustment for prognostic factors (n=111)*:
40 (36)Adjusted primary analysis for all factors
4 (4)Adjusted primary analysis for some factors
10 (9)Adjusted secondary analysis for all factors
45 (41)Not adjusted
12 (11)Unclear
163 (63)Balanced on centre or prognostic factors
Adjustment for centre or prognostic factors (n=163)*:
42 (26)Adjusted primary analysis for all factors
8 (5)Adjusted secondary analysis for all factors
3 (2)Adjusted for centre but not prognostic factors
14 (9)Adjusted for prognostic factors but not centre
74 (45)Not adjusted
22 (14)Unclear
No of prognostic factors balanced on:
53 (48)1
34 (31)2
11 (10)3
8 (7)4
2 (2)5
3 (3)8
*Trials were only assessed for whether they adjusted for centre or prognostic factors if they had balanced on these factors.
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Figures
Fig 1 Correlation in mean survival time between treatment groups under simple and stratified randomisation (simulated
data). Data were generated from the formula: survival time=3months+(6months)×(early disease stage)+random error, where
random error ~ N(0, 1)
Fig 2 Flow diagram of study selection
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